BioNTech AG Enters into Licensing Agreement with

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
119
BioNTech AG Enters into Licensing Agreement with CELLSCRIPT, LLC as it Advances Development of Messenger RNA Encoding Bispecific Antibodies and other Therapeutic Proteins

MAINZ, Germany, Sept. 06, 2017 (GLOBE NEWSWIRE) -- BioNTech AG, a fully integrated biotechnology company pioneering individualized cancer immunotherapy, today announced that it has entered into a broad and comprehensive non-exclusive patent licensing agreement with CELLSCRIPT, LLC covering nucleoside-modified messenger RNA (mRNA) for use in all in vivo applications, including therapeutic and non-therapeutic applications in humans and animals. Modified mRNAs covered by these technologies exhibit reduced innate immunogenicity, thereby allowing repeated dosing of mRNA therapeutics for the treatment of cancer and other diseases such as protein-deficient rare diseases. The modified mRNA technology is complementary to, but separate from, BioNTech's other mRNA technologies used in its clinical-stage cancer vaccines for the treatment of cancer. Financial details of the agreement were not disclosed.

The patents for CELLSCRIPT’s nucleoside-modified RNA technologies are the result of research conducted by Prof. Katalin Karikó, Ph.D. and Drew Weissman, M.D., Ph.D. at the University of Pennsylvania Medical School. Prof. Karikó, one of the world’s leading experts in mRNA biochemistry, with more than 30 years of experience, joined BioNTech in 2013. She has published more than 70 peer-reviewed papers and conducted groundbreaking research into the discovery that incorporation of modified nucleosides suppresses immunogenicity of RNA, consequently demonstrating the feasibility of using nucleoside-modified mRNA for protein replacement in vivo . She is co-inventor of therapeutic mRNA-related patents, including the patents for RNA containing modified nucleosides.

BioNTech recently reported preclinical animal data in Nature Medicine demonstrating that in vivo delivery of mRNA encoding T cell-engaging bispecific antibodies eliminated aggressive large tumors in mice.  Administering an mRNA encoding a bispecific antibody and thereby enabling the patient’s body to act as a factory, synthesizing the active therapeutic antibody itself, may profoundly reduce complexity and decrease drug development times compared to protein-based approaches.

“Our recently published data on bispecific antibodies reinforces the significant potential of this new therapeutic approach,” said Prof. Ugur Sahin, founder and CEO of BioNTech. “CELLSCRIPT’s technology will play an important role in our efforts to develop first-in-class mRNA-encoded antibodies and other therapies for the treatment of cancer and other diseases.”

BioNTech’s modified mRNA program complements the company’s larger portfolio of clinical-stage individualized RNA cancer vaccines. While modified mRNA is designed to be immunologically silent, BioNTech’s mRNA cancer vaccine treatments are optimized for appropriate immune stimulation and translation in immune cells.   

About BioNTech AG

BioNTech is Europe’s largest privately held biopharmaceutical company pioneering the development of individualized therapies for treatment of cancer and other diseases. The company combines all building blocks for individualized immunotherapy under one roof – from diagnostics and drug development to manufacturing. Its cutting-edge technologies range from individualized mRNA-based medicines through innovative chimeric antigen receptors and T-cell receptor-based products to novel bispecific antibody-based immunomodulators. BioNTech’s approach is validated by five top-tier corporate partnerships with Genentech, Genmab, Eli Lilly and Company, Sanofi and Bayer Animal Health. Founded in 2008, BioNTech’s financial shareholders include the MIG Fonds, Salvia and the Strüngmann Family Office, with the Strüngmann Family Office as the majority shareholder.

More information about BioNTech is available at www.biontech.de . 

About CELLSCRIPT, LLC

CELLSCRIPT, based in Madison, Wisconsin, USA, is focused on development and uses of RNA for translation in cells for clinical research and therapeutics. 

More information about CELLSCRIPT is available at www.cellscript.com .

For more information, please contact: General Inquiries: BioNTech AG Regina Jehle Tel: +49 6131 9084 1273 Email: Regina.Jehle@biontech.de US Media & Investors: ICR Healthcare James Heins / Stephanie Carrington Tel: +1 203 682 8251 Tel: +1 646 277 1282 Email: James.Heins@icrinc.com Email: Stephanie.Carrington@icrinc.com International Media & Investor Inquiries: akampion Dr. Ludger Wess / Ines-Regina Buth Tel: +49 40 8816 5964 Tel: +49 30 2363 2768 Email: info@akampion.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Jersey Teamsters Stand Firm for Fair Health Worker Deal

Updated Category News Views 117

ImageCare Workers Ready to Strike Normally, when we hear about health care, we're pretending it’s this well-oiled machine. But here we are, witnessing techs and aides at ImageCare gearing up to strike for the first time. Sussex County’s finest have had it up to their ears negotiating for a union contract that doesn’t treat them like an afterthought. Two-Year...

Continue Reading
Tech Job Market Surges with AI and IT Skills Spike

Updated Category News Views 92

Alright, folks, though we're not drowning in champagne just yet, there's a promising uptick in October's tech employment, signaling a rebound or at least some relief for tech pros and market watchers. CompTIA's numbers show a boost of 7,200 jobs in the tech industry while IT occupations expanded by 26,000 slots. That's no small feat when the general job scene elsewhere...

Continue Reading
CorelDRAW's Flexibility: A Designer's One-Time Buy?

Updated Category News Views 66

CorelDRAW: A Design Powerhouse Without Recurring Bills? Every so often, a software option comes along that piques my interest, and right now, it's CorelDRAW Graphics Suite. Consumer365 has shone a light on this nifty tool for its one-time purchase model—a breath of fresh air in the age of endless subscriptions that seem to drain more than enthusiasm as the months roll...

Continue Reading
Rutter Mills Expands Turkey Giveaway to Two Cities

Updated Category News Views 13

An Extra Helping of Community Spirit Rutter Mills is back on the scene again this Thanksgiving, slinging out a thousand turkeys to show their appreciation for the community they’ve called home since 1959. This initiative is the second iteration of their Turkey Drop, an event that's set to become a cherished tradition for years to come. Last year's event only teased the...

Continue Reading
WIC 2026: Global Connectivity and Cyber Futures

Updated Category News Views 144

Connectivity Takes Center Stage in Wuzhen When you throw 1,800 movers and shakers into a room focused on the future of the internet, sparks are gonna fly. That's exactly what's going down at the 2026 World Internet Conference in Wuzhen, China. Brass tacks: this ain't just another snooze-fest. The theme this year screams significance—'Open Source and Openness, Joined...

Continue Reading
VS Pharmtech Enhances Cancer Drug Efficiency, Eyes IPO

Updated Category News Views 86

Revolutionizing Cancer Care, One Dose at a Time Now, here's a twist worth chewing over your morning coffee: VS Pharmtech isn't concocting some newfangled miracle drug but is instead jazzing up the old ones. Their creation, VS-101, isn't just another treatment—it's a radiosensitizer designed to make existing therapies more potent without the toxic baggage. The Science...

Continue Reading
Pre-Owned Jet Inventory Rises; Price Trends Unclear

Updated Category News Views 83

October's Pre-Owned Aircraft Inventory: A Mixed Bag Nothing like leafing through October's data on pre-owned jets and feeling your stomach do that weird flip-flop. Inventory's nudging up, but it's still on its knees compared to last year's numbers. According to Sandhills Global's fresh aviation market reports, we got an increase in what's available on platforms like...

Continue Reading
212NYC Gala Celebrates Ad Industry's Human Touch

Updated Category News Views 98

The Advertising Gala with Heart When you toss nearly 300 advertising honchos into a room at Tribeca's Rooftop, you don't just get another bash; you get an industry checkpoint. This time, the 212NYC shindig on November 5, 2026, wasn't just about stroking egos. It was about spotlighting the soul in business, right when AI threatens to run wild with it. Navigating AI's...

Continue Reading
QORAI CORP's Q4 Nexus: A New AI Frontier

Updated Category News Views 51

Breakthrough in AI: Enter Q4 Nexus It's not every day you see a tech player emerge with something genuinely fresh—QORAI CORP is shaking up the scene with its Q4 Nexus platform. This isn't just another AI model upgrade. We're talking about a rethink of the very architecture we rely on to power these systems. Founder Robby Joshi's brainchild, Q4 Nexus, jazzes up the AI...

Continue Reading
Sass Magazine's 2026 COZY Issue Embraces Intentional Joy

Updated Category News Views 70

An Unexpected Shift in Sass's Seasonal Focus When you think November and December, it's easy to picture the hustle and bustle of holiday preparations—shopping, parties, running around. But toss all that hullabaloo out the window, because Sass Magazine has thrown a curveball for their 2026 release. They're steering the ship towards the calm, with their COZY Issue shaping...

Continue Reading

Top 5 Most Recently Viewed Articles

Crypto ETFs Make Waves: Dogecoin and XRP Soar in Trading

Updated Category News Views 209

Exciting Developments in Cryptocurrency ETFs In a remarkable turn of events for the cryptocurrency market, Dogecoin (DOGE) and XRP are experiencing a surge as they mark groundbreaking trading volumes on the launch day of their respective exchange-traded funds (ETFs). This uptick comes on the heels of the SEC's announcement regarding enhanced listing standards for...

Continue Reading
Ashling's New Feat: Microsoft Recognition in AI

Updated Category News Views 159

Microsoft's Stamp of Approval for Ashling Ah, recognition—it's not just for egos. When Ashling, an AI consultancy heavyweight, gets a nod from Microsoft, it's worth more than a footnote in the company newsletter. This isn't some participation trophy. Nope, it's a badge saying they know their Data & AI, and Digital & App Innovation inside out. On October 29, 2026,...

Continue Reading
Zoom Communications Exceeds Expectations with FY2025 Report

Updated Category News Views 933

Zoom's Impressive Year-End Financial Report Zoom Communications, Inc. (NASDAQ: ZM) recently published its financial results for the fourth quarter and the entirety of fiscal year 2025, reflecting substantial growth and innovation. With a total revenue of $1,184.1 million for the fourth quarter, this marks a year-over-year increase of 3.3%. When evaluated in constant...

Continue Reading
Investors Alert: Key Class Action Deadlines Upcoming

Updated Category News Views 230

Class Action Lawsuits Overview Investors, pay close attention! Class action lawsuits are now underway for several publicly-traded companies, and shareholder involvement is crucial. One such entity actively pursuing these cases is The Law Offices of Frank R. Cruz, reminding affected shareholders of their rights. Time is of the essence, as there are strict deadlines for...

Continue Reading
Fermi Inc. (FRMI) Faces Significant Setback with Tenant News

Updated Category News Views 182

Fermi Inc. Shares Decline Significantly Following Contract Issues On a recent day, investors of Fermi Inc. (NASDAQ: FRMI) experienced a notable drop in share prices, with a staggering decline of about 33%. This drop followed the announcement regarding the termination of an essential contract with a prospective anchor tenant, known as the First Tenant, for Fermi's...

Continue Reading